目的 观察百癣夏塔热胶囊联合枸地氯雷他定治疗慢性荨麻疹的临床疗效。方法 选取2015年10月—2017年5月东莞市茶山医院收治的慢性荨麻疹患者84例，随机分为对照组和治疗组，每组各42例。对照组口服枸地氯雷他定片，1片/次，1次/d。治疗组在对照组治疗基础上口服百癣夏塔热胶囊，35~45 kg者，2粒/次，2次/d；45 kg及以上者，2粒/次，3次/d。两组患者均连续治疗4周。观察两组的临床疗效，比较两组治疗前后症状积分、血清学指标和免疫功能的变化情况。对两组进行3个月的随访，观察复发情况。结果 治疗后，对照组和治疗组的总有效率分别为71.43%、90.48%，两组比较差异有统计学意义（P < 0.05）。治疗后，两组皮肤瘙痒积分、风团直径积分、风团数目积分、免疫球蛋白E（IgE）、白细胞介素-4（IL-4）、IL-18、IL-33、CD⁸⁺均显著降低，干扰素-γ（IFN-γ）、CD⁴⁺、CD⁴⁺/CD⁸⁺明显上升，同组治疗前后比较差异有统计学意义（P < 0.05）；治疗后，治疗组皮肤瘙痒积分、风团直径积分、风团数目积分、IgE、IL-4、IL-18、IL-33、CD⁸⁺均低于对照组，IFN-γ、CD⁴⁺、CD⁴⁺/CD⁸⁺高于对照组，两组比较差异具有统计学意义（P < 0.05）。随访期间，对照组和治疗组的复发率分别为19.05%、2.38%，两组比较差异有统计学意义（P < 0.05）。结论 百癣夏塔热胶囊联合枸地氯雷他定治疗慢性荨麻疹具有较好的临床疗效，可改善患者症状和免疫状态，同时可有效降低复发率，具有一定的推广应用价值。

Objective To observe the clinical efficacy of Baixuan Xiatare Capsules combined with desloratadine citrate disodium in treating of chronic urticarial. Methods Patients (84 cases) with chronic urticaria in Chashan Hospital of Dongguan from October 2015 to May 2017were randomly divided into control (42 cases) and treatment (42 cases) groups. Patients in the control group were po administered with Desloratadine Citrate Disodium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Baixuan Xiatare Capsules on the basis of the control group, weight from 35 kg to 45 kg, 2 grains/time, twice daily; weight above 45 kg, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of symptom scores, serological indexes and immune function in two groups before and after treatment were compared. The two groups were followed up for 3 months, and the recurrence was observed. Results After treatment, the clinical efficacy in the control and treatment groups were 71.43% and 90.48%, respectively, and there was difference between two groups (P < 0.05). After treatment, skin itch score, wind group diameter score, wind group number score, IgE, IL-4, IL-18, IL-33, and CD⁸⁺ were decreased, but IFN-γ, CD⁴⁺, CD⁴⁺/CD⁸⁺ increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, skin itch score, wind group diameter score, wind group number score, IgE, IL-4, IL-18, IL-33, and CD⁸⁺ in the treatment group were lower than those in the control group, but IFN-γ, CD⁴⁺, CD⁴⁺/CD⁸⁺ were higher than those in the control group, and there was difference between two groups (P < 0.05). During the follow-up period, the recurrence rates of the control group and the treatment group were 19.05% and 2.38% respectively, and there was difference between two groups (P < 0.05). Conclusion Baixuan Xiatare Capsules combined with desloratadine citrate disodium has clinical curative effect in treating of chronic urticarial, and can improve the symptoms and immune status, and can effectively reduce the recurrence rate, which has a certain clinical application value.